Institut Mérieux is strengthening its position in the share capital of bioMérieux through the acquisition of an additional 1% stake, bringing its holding to nearly 60%. This decision reaffirms its confidence in the Group’s strategy and its long-term commitment to public health.
Following a meeting held on April 27 under the chairmanship of Alain Mérieux, the Board of Directors of Institut Mérieux approved the acquisition of an additional 1% stake in bioMérieux, thereby increasing its shareholding and reaffirming its confidence in the Group’s strategic direction and role as a world leader in in vitro diagnostics.
As a result of this acquisition, Institut Mérieux now holds close to 60% of bioMérieux’s share capital.
“This share purchase confirms of our long–term support and confidence in bioMérieux’s strategic and operational roadmap as well as in the dedication of our talented teams” said Alexandre Mérieux, Vice Chairman of the Board of Directors of Institut Mérieux and Chairman of the Board of Directors of bioMérieux. “bioMérieux has a clear ambition to accelerate sustainable and profitable growth by leveraging breakthrough innovation in diagnostics, strengthening operational excellence, and expanding its global impact. As a majority shareholder, Institut Mérieux is fully aligned with this strategy and remains deeply committed to supporting bioMérieux in its mission to serve public health and improve patient care worldwide”.